abstract |
The invention provides methods of using the PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or suppress pro-inflammatory cascades in patients at risk of or suffering from an inflammatory response or symptom of allergy through CD44 antagonism, regulation of pro-inflammatory cytokine production, inhibition of NF-B translocation, and / or to facilitate the removal of inflammation-inducing cellular or matrix debris or allergens. |